Iris Dotan

18.8k total citations · 2 hit papers
320 papers, 9.5k citations indexed

About

Iris Dotan is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Iris Dotan has authored 320 papers receiving a total of 9.5k indexed citations (citations by other indexed papers that have themselves been cited), including 206 papers in Genetics, 132 papers in Epidemiology and 102 papers in Surgery. Recurrent topics in Iris Dotan's work include Inflammatory Bowel Disease (201 papers), Microscopic Colitis (109 papers) and Eosinophilic Esophagitis (32 papers). Iris Dotan is often cited by papers focused on Inflammatory Bowel Disease (201 papers), Microscopic Colitis (109 papers) and Eosinophilic Esophagitis (32 papers). Iris Dotan collaborates with scholars based in Israel, United States and United Kingdom. Iris Dotan's co-authors include Dan Canaani, Henit Yanai, Chengyu Liang, Pinghui Feng, Bonsu Ku, Byung‐Ha Oh, Jae U. Jung, Hagit Tulchinsky, Silvio Danese and Matthieu Allez and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Iris Dotan

303 papers receiving 9.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

2021 1.5k citations Dan Turner, Silvio Danese et al. profile →
Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG

2006 819 citations Iris Dotan et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Iris Dotan Israel	49	5.0k	4.2k	2.4k	2.0k	1.9k	320	9.5k
Stephan R. Vavricka Switzerland	50	5.4k 1.1×	4.3k 1.0×	3.0k 1.3×	1.5k 0.8×	2.2k 1.2×	240	11.0k
Alessandro Armuzzi Italy	52	5.8k 1.1×	4.4k 1.0×	3.5k 1.5×	2.1k 1.0×	1.5k 0.8×	435	10.4k
Mark S. Silverberg Canada	51	5.6k 1.1×	3.8k 0.9×	2.0k 0.9×	2.3k 1.1×	2.0k 1.1×	249	8.7k
Fernando Magro Portugal	41	5.5k 1.1×	4.2k 1.0×	2.4k 1.0×	1.5k 0.7×	1.1k 0.6×	307	8.6k
William A. Faubion United States	46	4.1k 0.8×	3.3k 0.8×	2.4k 1.0×	2.6k 1.3×	1.4k 0.7×	195	8.9k
Torsten Kucharzik Germany	50	3.7k 0.7×	2.6k 0.6×	2.5k 1.1×	2.6k 1.3×	1.8k 1.0×	198	9.2k
Hans Herfarth United States	55	4.7k 0.9×	4.2k 1.0×	3.0k 1.3×	3.0k 1.5×	3.1k 1.7×	264	12.1k
R. D’Incà Italy	49	3.6k 0.7×	2.5k 0.6×	2.1k 0.9×	1.2k 0.6×	1.6k 0.8×	229	7.5k
Daniël W. Hommes Netherlands	58	5.5k 1.1×	3.7k 0.9×	2.9k 1.2×	2.9k 1.4×	2.8k 1.5×	217	12.6k
P. Rutgeerts Belgium	51	7.5k 1.5×	5.7k 1.3×	3.4k 1.4×	2.1k 1.0×	1.3k 0.7×	189	11.0k

Countries citing papers authored by Iris Dotan

Since Specialization

Citations

This map shows the geographic impact of Iris Dotan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iris Dotan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iris Dotan more than expected).

Fields of papers citing papers by Iris Dotan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iris Dotan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iris Dotan. The network helps show where Iris Dotan may publish in the future.

Co-authorship network of co-authors of Iris Dotan

This figure shows the co-authorship network connecting the top 25 collaborators of Iris Dotan. A scholar is included among the top collaborators of Iris Dotan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iris Dotan. Iris Dotan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Boneh, Rotem Sigall, S Organ, Henit Yanai, et al.. (2025). P1323 Differential Microbiome Responses to the Crohn’s Disease Exclusion Diet in Pediatric vs. Adult Populations: Insights from Randomized Controlled Trials. Journal of Crohn s and Colitis. 19(Supplement_1). i2383–i2383.

Solitano, Virginia, Çharles N. Bernstein, Iris Dotan, et al.. (2025). Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health response. Nature Reviews Gastroenterology & Hepatology. 22(6). 438–452. 5 indexed citations

Atia, Ohad, Amir Ben‐Tov, Mehdi Osooli, et al.. (2024). The Epidemiology of Inflammatory Bowel Diseases During the COVID-19 Pandemic: Comparison of Two Nationwide Cohorts. Journal of Crohn s and Colitis. 18(8). 1241–1249. 5 indexed citations

Avni‐Biron, Irit, Ervin Tóth, Jacob E. Ollech, et al.. (2024). The Role of Small-Bowel Capsule Endoscopy in the Diagnostic Algorithm of Complicated Perianal Disease. Diagnostics. 14(16). 1733–1733. 1 indexed citations

Weisband, Yiska Loewenberg, et al.. (2024). P1116 Risk of fractures in children and adults with inflammatory bowel disease: A report from the epi-IIRN. Journal of Crohn s and Colitis. 18(Supplement_1). i1989–i1990. 1 indexed citations

Godny, Lihi, Ian White, Nir Wasserberg, et al.. (2024). Factors Associated With Biologic Therapy After Ileal Pouch–Anal Anastomosis in Patients With Ulcerative Colitis. Inflammatory Bowel Diseases. 31(7). 1934–1942. 1 indexed citations

Focht, Gili, Shira Greenfeld, Revital Kariv, et al.. (2024). Enteral nutrition compared with corticosteroids in children with Crohn's disease: A long‐term nationwide study from the epi‐IIRN. Alimentary Pharmacology & Therapeutics. 60(2). 224–232. 2 indexed citations

Konikoff, Tom, Henit Yanai, Uri Kopylov, et al.. (2024). Precision medicine: Externally validated explainable AI support tool for predicting sustainability of infliximab and vedolizumab in ulcerative colitis. Digestive and Liver Disease. 56(12). 2069–2076.

Atia, Ohad, Gili Focht, Shira Greenfeld, et al.. (2023). Durability of the First Biologic in Patients with Crohn’s Disease: A Nationwide Study from the epi-IIRN. Journal of Crohn s and Colitis. 18(1). 38–46. 6 indexed citations

10.

Ledder, Oren, Esther Orlanski‐Meyer, Yiska Loewenberg Weisband, et al.. (2023). Residence in Peripheral Regions and Low Socioeconomic Status Are Associated With Worse Outcomes of Inflammatory Bowel Diseases: A Nationwide Study From the epi-IIRN. Inflammatory Bowel Diseases. 30(1). 1–8. 3 indexed citations

11.

Atia, Ohad, Idan Goren, Shira Greenfeld, et al.. (2023). 5‐aminosalicylate maintenance is not superior to no maintenance in patients with newly diagnosed Crohn's disease—A nationwide cohort study. Alimentary Pharmacology & Therapeutics. 57(9). 1004–1013. 12 indexed citations

12.

Reshef, Leah, et al.. (2022). Escherichia coli Strains from Patients with Inflammatory Bowel Diseases have Disease-specific Genomic Adaptations. Journal of Crohn s and Colitis. 16(10). 1584–1597. 9 indexed citations

13.

Avni‐Biron, Irit, Eran Hadar, Michal Neeman, et al.. (2022). SARS-CoV-2 IgG Antibody Levels in Women with IBD Vaccinated during Pregnancy. Vaccines. 10(11). 1833–1833. 1 indexed citations

14.

Gorelik, Yuri, Sigal Pressman, Gili Focht, et al.. (2021). Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFα therapy in inflammatory bowel disease patients: a report from the epi-IIRN. Gut. 71(2). 287–295. 17 indexed citations

15.

Atia, Ohad, Esther Orlanski‐Meyer, Shira Greenfeld, et al.. (2021). Improved Outcomes of Paediatric and Adult Crohn’s Disease and Association With Emerging Use of Biologics–A Nationwide Study From the Epi-IIRN. Journal of Crohn s and Colitis. 16(5). 778–785. 19 indexed citations

16.

Loftus, Edward V., et al.. (2020). Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1. SHILAP Revista de lepidopterología.

17.

Snir, Yifat, Haim Leibovitzh, Yaara Leibovici‐Weissman, et al.. (2020). Dose‐dependent association of proton pump inhibitors use with gastric intestinal metaplasia among Helicobacter pylori‐positive patients. United European Gastroenterology Journal. 9(3). 343–353. 4 indexed citations

18.

Boltin, Doron, Zohar Levi, Tsachi Tsadok Perets, et al.. (2018). Correlation between Quantitative ¹³C-Urea Breath Test and Helicobacter pylori Treatment Success in a Population-Based Cohort. Gastroenterology Research and Practice. 2018. 1–6. 9 indexed citations

19.

Perets, Tsachi Tsadok, Rachel Gingold‐Belfer, Haim Leibovitzh, et al.. (2018). Optimization of ¹³C‐urea breath test threshold levels for the detection of Helicobacter pylori infection in a national referral laboratory. Journal of Clinical Laboratory Analysis. 33(2). e22674–e22674. 16 indexed citations

20.

Ferrante, Marc, Marieke Pierik, Liesbet Henckaerts, et al.. (2006). A panel of anti-glycan antibodies (gASCA, ALCA, ACCA and AMCA) in the diagnosis and differential diagnosis of IBD. Ghent University Academic Bibliography (Ghent University). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact